(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of 18.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.39%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.36%.
Immatics Nv's revenue in 2026 is $56,783,529.On average, 13 Wall Street analysts forecast IMTX's revenue for 2026 to be $6,083,759,370, with the lowest IMTX revenue forecast at $2,078,107,196, and the highest IMTX revenue forecast at $9,150,375,234. On average, 12 Wall Street analysts forecast IMTX's revenue for 2027 to be $7,660,037,196, with the lowest IMTX revenue forecast at $1,090,537,028, and the highest IMTX revenue forecast at $16,583,295,424.
In 2028, IMTX is forecast to generate $13,610,931,777 in revenue, with the lowest revenue forecast at $5,492,102,140 and the highest revenue forecast at $26,634,630,681.